Yuhan Corporation (000105.KS)
KRW 101900.0
(-3.04%)
KRW 101900.0
(-3.04%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 489.94 Billion KRW | 11.82% |
| 2022 | 482.17 Billion KRW | 1.29% |
| 2021 | 476.05 Billion KRW | 0.4% |
| 2020 | 474.16 Billion KRW | 13.35% |
| 2019 | 418.31 Billion KRW | 15.03% |
| 2018 | 363.66 Billion KRW | 8.26% |
| 2017 | 335.91 Billion KRW | 15.18% |
| 2016 | 291.64 Billion KRW | 14.45% |
| 2015 | 254.83 Billion KRW | 5.72% |
| 2014 | 241.04 Billion KRW | 3.93% |
| 2013 | 231.93 Billion KRW | 9.94% |
| 2012 | 210.96 Billion KRW | 3.98% |
| 2011 | 202.88 Billion KRW | 5.11% |
| 2010 | 193.03 Billion KRW | -4.88% |
| 2009 | 202.93 Billion KRW | -2.55% |
| 2008 | 208.24 Billion KRW | 21.11% |
| 2007 | 171.94 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 193.03 Billion KRW | -14.97% |
| 2024 Q1 | 168.39 Billion KRW | -60.95% |
| 2023 Q4 | 431.17 Billion KRW | 400.24% |
| 2023 FY | 539.16 Billion KRW | 11.82% |
| 2023 Q1 | 112.93 Billion KRW | -4.81% |
| 2023 Q2 | -125.52 Billion KRW | -211.15% |
| 2023 Q3 | -143.61 Billion KRW | -14.41% |
| 2022 FY | 482.17 Billion KRW | 1.29% |
| 2022 Q2 | 128.5 Billion KRW | 17.11% |
| 2022 Q1 | 109.73 Billion KRW | -16.25% |
| 2022 Q4 | 118.64 Billion KRW | -5.31% |
| 2022 Q3 | 125.29 Billion KRW | -2.49% |
| 2021 Q1 | 101.07 Billion KRW | -32.64% |
| 2021 Q2 | 117.71 Billion KRW | 16.47% |
| 2021 FY | 476.05 Billion KRW | 0.4% |
| 2021 Q3 | 126.24 Billion KRW | 7.24% |
| 2021 Q4 | 131.02 Billion KRW | 3.79% |
| 2020 Q1 | 90.29 Billion KRW | -21.51% |
| 2020 Q3 | 115.92 Billion KRW | -1.68% |
| 2020 Q4 | 150.05 Billion KRW | 29.44% |
| 2020 FY | 474.16 Billion KRW | 13.35% |
| 2020 Q2 | 117.9 Billion KRW | 30.58% |
| 2019 Q4 | 115.02 Billion KRW | 13.04% |
| 2019 Q2 | 104.34 Billion KRW | 7.39% |
| 2019 Q1 | 97.17 Billion KRW | -1.64% |
| 2019 FY | 418.31 Billion KRW | 15.03% |
| 2019 Q3 | 101.76 Billion KRW | -2.48% |
| 2018 Q2 | 92.37 Billion KRW | 21.3% |
| 2018 FY | 363.66 Billion KRW | 8.26% |
| 2018 Q4 | 98.79 Billion KRW | 2.54% |
| 2018 Q3 | 96.34 Billion KRW | 4.3% |
| 2018 Q1 | 76.15 Billion KRW | -15.0% |
| 2017 Q4 | 89.59 Billion KRW | 7.17% |
| 2017 FY | 335.91 Billion KRW | 15.18% |
| 2017 Q1 | 73.79 Billion KRW | -3.5% |
| 2017 Q2 | 88.92 Billion KRW | 20.5% |
| 2017 Q3 | 83.59 Billion KRW | -5.98% |
| 2016 Q1 | 63.13 Billion KRW | -15.85% |
| 2016 Q2 | 76.01 Billion KRW | 20.4% |
| 2016 Q3 | 76.01 Billion KRW | 0.0% |
| 2016 FY | 291.64 Billion KRW | 14.45% |
| 2016 Q4 | 76.47 Billion KRW | 0.59% |
| 2015 Q3 | 65.02 Billion KRW | 9.26% |
| 2015 Q4 | 75.02 Billion KRW | 15.38% |
| 2015 FY | 254.83 Billion KRW | 5.72% |
| 2015 Q1 | 55.26 Billion KRW | -11.74% |
| 2015 Q2 | 59.51 Billion KRW | 7.7% |
| 2014 Q1 | 54.75 Billion KRW | -9.67% |
| 2014 FY | 241.04 Billion KRW | 3.93% |
| 2014 Q4 | 62.61 Billion KRW | 2.41% |
| 2014 Q3 | 61.14 Billion KRW | -2.21% |
| 2014 Q2 | 62.52 Billion KRW | 14.18% |
| 2013 Q3 | 55.55 Billion KRW | -10.31% |
| 2013 Q4 | 60.62 Billion KRW | 9.12% |
| 2013 FY | 231.93 Billion KRW | 9.94% |
| 2013 Q1 | 53.82 Billion KRW | -2.76% |
| 2013 Q2 | 61.93 Billion KRW | 15.06% |
| 2012 Q2 | 52.59 Billion KRW | 12.72% |
| 2012 Q1 | 46.65 Billion KRW | 0.0% |
| 2012 Q3 | 56.63 Billion KRW | 7.68% |
| 2012 Q4 | 55.35 Billion KRW | -2.25% |
| 2012 FY | 210.96 Billion KRW | 3.98% |
| 2011 Q1 | 48.24 Billion KRW | -8.45% |
| 2011 FY | 202.88 Billion KRW | 5.11% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 47.36 Billion KRW | -5.76% |
| 2011 Q2 | 50.26 Billion KRW | 4.18% |
| 2010 Q3 | 44.33 Billion KRW | -3.63% |
| 2010 Q2 | 46 Billion KRW | 0.59% |
| 2010 Q1 | 45.73 Billion KRW | -9.76% |
| 2010 Q4 | 52.69 Billion KRW | 18.86% |
| 2010 FY | 193.03 Billion KRW | -4.88% |
| 2009 Q3 | 45.7 Billion KRW | -9.41% |
| 2009 Q4 | 50.68 Billion KRW | 10.89% |
| 2009 FY | 202.93 Billion KRW | -2.55% |
| 2009 Q1 | 49.91 Billion KRW | -7.03% |
| 2009 Q2 | 50.45 Billion KRW | 1.08% |
| 2008 Q4 | 53.68 Billion KRW | 6.08% |
| 2008 FY | 208.24 Billion KRW | 21.11% |
| 2008 Q1 | 47.87 Billion KRW | -0.13% |
| 2008 Q2 | 50.72 Billion KRW | 5.96% |
| 2008 Q3 | 50.6 Billion KRW | -0.23% |
| 2007 FY | 171.94 Billion KRW | 0.0% |
| 2007 Q1 | 37.52 Billion KRW | 0.0% |
| 2007 Q2 | 39.69 Billion KRW | 5.8% |
| 2007 Q3 | 43.26 Billion KRW | 9.0% |
| 2007 Q4 | 47.93 Billion KRW | 10.79% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -936.836% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | -64.416% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | -75.961% |
| HANDOK Inc. | 153.76 Billion KRW | -218.626% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -607.875% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | -59.613% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -1072.413% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 19.809% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -580.637% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -181.338% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -1123.239% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -423.717% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -327.061% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -936.836% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -1053.579% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -552.832% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -735.453% |
| JW Holdings Corporation | 301.25 Billion KRW | -62.634% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | -87.75% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | -19.892% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -105.075% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -283.761% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -617.228% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -645.148% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -180.087% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -936.836% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | -96.669% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 12.577% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -105.075% |
| Yuhan Corporation | 489.94 Billion KRW | 0.0% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -152.988% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -605.276% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -774.402% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -105.075% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -287.637% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -314.456% |
| CKD Bio Corp. | 25.19 Billion KRW | -1844.555% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -120.697% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -196.733% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -637.676% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -283.761% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | -39.699% |
| Boryung Corporation | 285.16 Billion KRW | -71.813% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -459.668% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -181.338% |
| JW Lifescience Corporation | 20.26 Billion KRW | -2318.101% |